231 related articles for article (PubMed ID: 35768165)
1. Genome-scale CRISPR-Cas9 screen reveals novel regulators of B7-H3 in tumor cells.
Zhao S; Wang Y; Yang N; Mu M; Wu Z; Li H; Tang X; Zhong K; Zhang Z; Huang C; Cao T; Zheng M; Wang G; Nie C; Yang H; Guo G; Zhou L; Zheng X; Tong A
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35768165
[TBL] [Abstract][Full Text] [Related]
2. B7-H3 Suppresses Antitumor Immunity via the CCL2-CCR2-M2 Macrophage Axis and Contributes to Ovarian Cancer Progression.
Miyamoto T; Murakami R; Hamanishi J; Tanigaki K; Hosoe Y; Mise N; Takamatsu S; Mise Y; Ukita M; Taki M; Yamanoi K; Horikawa N; Abiko K; Yamaguchi K; Baba T; Matsumura N; Mandai M
Cancer Immunol Res; 2022 Jan; 10(1):56-69. PubMed ID: 34799346
[TBL] [Abstract][Full Text] [Related]
3. MiR-29c downregulates tumor-expressed B7-H3 to mediate the antitumor NK-cell functions in ovarian cancer.
Deng M; Wu D; Zhang Y; Jin Z; Miao J
Gynecol Oncol; 2021 Jul; 162(1):190-199. PubMed ID: 33875234
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of the B7-H3 immune checkpoint limits hepatocellular carcinoma progression by enhancing T lymphocyte-mediated immune cytotoxicity in vitro and in vivo.
Zhou Z; Yu X; Chen Y; Tan X; Liu W; Hua W; Chen L; Zhang W
Clin Transl Oncol; 2023 Apr; 25(4):1067-1079. PubMed ID: 36512305
[TBL] [Abstract][Full Text] [Related]
5. Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells.
Du H; Hirabayashi K; Ahn S; Kren NP; Montgomery SA; Wang X; Tiruthani K; Mirlekar B; Michaud D; Greene K; Herrera SG; Xu Y; Sun C; Chen Y; Ma X; Ferrone CR; Pylayeva-Gupta Y; Yeh JJ; Liu R; Savoldo B; Ferrone S; Dotti G
Cancer Cell; 2019 Feb; 35(2):221-237.e8. PubMed ID: 30753824
[TBL] [Abstract][Full Text] [Related]
6. Deficiency of tumor-expressed B7-H3 augments anti-tumor efficacy of anti-PD-L1 monotherapy rather than the combined chemoimmunotherapy in ovarian cancer.
Huang M; Luo J; Ji X; Hu M; Xue Y; Liu Q
Pharmacol Res; 2022 Dec; 186():106512. PubMed ID: 36272639
[TBL] [Abstract][Full Text] [Related]
7. Activation of the TLR2-mediated downstream signaling pathways NF-κB and MAPK is responsible for B7-H3-augmented inflammatory response during S. pneumoniae infection.
Chen X; Meng X; Foley NM; Shi X; Liu M; Chai Y; Li Y; Redmond HP; Wang J; Wang JH
J Neuroimmunol; 2017 Sep; 310():82-90. PubMed ID: 28778451
[TBL] [Abstract][Full Text] [Related]
8. High expression of B7-H3 on stromal cells defines tumor and stromal compartments in epithelial ovarian cancer and is associated with limited immune activation.
MacGregor HL; Sayad A; Elia A; Wang BX; Katz SR; Shaw PA; Clarke BA; Crome SQ; Robert-Tissot C; Bernardini MQ; Nguyen LT; Ohashi PS
J Immunother Cancer; 2019 Dec; 7(1):357. PubMed ID: 31892360
[TBL] [Abstract][Full Text] [Related]
9. Immunoregulatory protein B7-H3 regulates cancer stem cell enrichment and drug resistance through MVP-mediated MEK activation.
Liu Z; Zhang W; Phillips JB; Arora R; McClellan S; Li J; Kim JH; Sobol RW; Tan M
Oncogene; 2019 Jan; 38(1):88-102. PubMed ID: 30082909
[TBL] [Abstract][Full Text] [Related]
10. Tumor-expressed B7-H3 mediates the inhibition of antitumor T-cell functions in ovarian cancer insensitive to PD-1 blockade therapy.
Cai D; Li J; Liu D; Hong S; Qiao Q; Sun Q; Li P; Lyu N; Sun T; Xie S; Guo L; Ni L; Jin L; Dong C
Cell Mol Immunol; 2020 Mar; 17(3):227-236. PubMed ID: 31611650
[TBL] [Abstract][Full Text] [Related]
11. Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy.
Zhao B; Li H; Xia Y; Wang Y; Wang Y; Shi Y; Xing H; Qu T; Wang Y; Ma W
J Hematol Oncol; 2022 Oct; 15(1):153. PubMed ID: 36284349
[TBL] [Abstract][Full Text] [Related]
12. Decreased expression of B7-H3 reduces the glycolytic capacity and sensitizes breast cancer cells to AKT/mTOR inhibitors.
Nunes-Xavier CE; Karlsen KF; Tekle C; Pedersen C; Øyjord T; Hongisto V; Nesland JM; Tan M; Sahlberg KK; Fodstad Ø
Oncotarget; 2016 Feb; 7(6):6891-901. PubMed ID: 26771843
[TBL] [Abstract][Full Text] [Related]
13. B7-H3 augments the pro-angiogenic function of tumor-associated macrophages and acts as a novel adjuvant target for triple-negative breast cancer therapy.
Cheng N; Bei Y; Song Y; Zhang W; Xu L; Zhang W; Yang N; Bai X; Shu Y; Shen P
Biochem Pharmacol; 2021 Jan; 183():114298. PubMed ID: 33153969
[TBL] [Abstract][Full Text] [Related]
14. p38 MAPK activation through B7-H3-mediated DUSP10 repression promotes chemoresistance.
Flem-Karlsen K; Tekle C; Øyjord T; Flørenes VA; Mælandsmo GM; Fodstad Ø; Nunes-Xavier CE
Sci Rep; 2019 Apr; 9(1):5839. PubMed ID: 30967582
[TBL] [Abstract][Full Text] [Related]
15. Tandem CAR-T cells targeting CD70 and B7-H3 exhibit potent preclinical activity against multiple solid tumors.
Yang M; Tang X; Zhang Z; Gu L; Wei H; Zhao S; Zhong K; Mu M; Huang C; Jiang C; Xu J; Guo G; Zhou L; Tong A
Theranostics; 2020; 10(17):7622-7634. PubMed ID: 32685008
[No Abstract] [Full Text] [Related]
16. Monoclonal antibody-based immunotherapy of ovarian cancer: targeting ovarian cancer cells with the B7-H3-specific mAb 376.96.
Fauci JM; Sabbatino F; Wang Y; Londoño-Joshi AI; Straughn JM; Landen CN; Ferrone S; Buchsbaum DJ
Gynecol Oncol; 2014 Jan; 132(1):203-10. PubMed ID: 24216048
[TBL] [Abstract][Full Text] [Related]
17. B7-H3/CD276: An Emerging Cancer Immunotherapy.
Zhou WT; Jin WL
Front Immunol; 2021; 12():701006. PubMed ID: 34349762
[TBL] [Abstract][Full Text] [Related]
18. Multi-Omics Data Analyses Identify B7-H3 as a Novel Prognostic Biomarker and Predict Response to Immune Checkpoint Blockade in Head and Neck Squamous Cell Carcinoma.
Lin W; Xu Y; Gao J; Zhang H; Sun Y; Qiu X; Huang Q; Kong L; Lu JJ
Front Immunol; 2021; 12():757047. PubMed ID: 34675936
[TBL] [Abstract][Full Text] [Related]
19. B7-H3 Augments Inflammatory Responses and Exacerbates Brain Damage via Amplifying NF-κB p65 and MAPK p38 Activation during Experimental Pneumococcal Meningitis.
Chen X; Li Y; Blankson S; Liu M; Huang D; Redmond HP; Huang J; Wang JH; Wang J
PLoS One; 2017; 12(1):e0171146. PubMed ID: 28141831
[TBL] [Abstract][Full Text] [Related]
20. Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity.
Loo D; Alderson RF; Chen FZ; Huang L; Zhang W; Gorlatov S; Burke S; Ciccarone V; Li H; Yang Y; Son T; Chen Y; Easton AN; Li JC; Rillema JR; Licea M; Fieger C; Liang TW; Mather JP; Koenig S; Stewart SJ; Johnson S; Bonvini E; Moore PA
Clin Cancer Res; 2012 Jul; 18(14):3834-45. PubMed ID: 22615450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
